Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Alumis' TYK2 drug fails in lupus trial; CEO sees 'clear path forward'

Alumis' lead drug program suffered a clinical setback Tuesday as the San Francisco biotech reported its TYK2 pill failed a mid-stage lupus study. The results put a damper on what has ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Also reported by 1 other outlet

Read the original at endpoints.news →

More in Health & Medicine

More from Tuesday 1 September →